Many clinical trials have been conducted to evaluate the effects of FDA approved tyrosine kinase inhibitors (TKI) targeting EGFR in PCa – including cetuximab (17, 18), gefitinib (19–24) and erlotinib (25, 26). Here, EGFR is linked to posterior cortical atrophy.